![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.235 | -4.94% | 4.52 | 4.35 | 4.69 | 4.75 | 4.36 | 4.75 | 212,429 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.50 | 9.58M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/8/2020 21:59 | Thanks... If all those treatment use cases are approved I can see £10bn. If a takeover battle breaks out for SNG I could see north of that, maybe £15bn, maybe at a push even £20bn. But never £40bn, not in this reality... | ![]() sloppyjoe2 | |
23/8/2020 21:49 | Now you're getting it. | ![]() festario |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions